Safety and acceptability of intravaginal rings releasing estradiol and progesterone

References

• Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol. 2015;100(11):3975–4011.
   PubMed Web of Science ®Google Scholar
• Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87–94.
   PubMed Web of Science ®Google Scholar
• ACOG Practice Bulletin No 141: management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202–216.
   PubMed Web of Science ®Google Scholar
• Jane FM, Davis SR. A practitioner’s toolkit for managing the menopause. Climacteric. 2014;17(5):564–579.
   PubMed Web of Science ®Google Scholar
• Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85(2):304–313.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the women’s health initiative randomized trial. JAMA. 2003;290(13):1739–1748.
   PubMed Web of Science ®Google Scholar
• Maclennan AH, Broadbent JL, Lester S, et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004; Oct 182004(4):Cd002978.
   PubMedGoogle Scholar
• Hull L, Stuckey BGA, Hartman K, et al. Evaluation of 28-Day estradiol and progesterone vaginal rings in a phase 1 clinical pharmacokinetic study. Menopause. 2023;2023:148.
   Google Scholar
• Al-Azzawi F, Buckler HM. Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms. Climacteric. 2003;6(2):118–127.
   PubMed Web of Science ®Google Scholar
• Buckler H, Al-Azzawi F, Group T. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women. Int J Obs Gyn. 2003;110(8):753–759.
   PubMed Web of Science ®Google Scholar
• Bachmann G. The estradiol vaginal ring; a study of existing clinical data. Maturitas. 1995;22: S21–S29.
   PubMed Web of Science ®Google Scholar
• Casper F, Petri E. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Int Urogynecol J. 1999;10(3):171–176.
   Google Scholar
• Dezarnaulds G, Fraser IS. Vaginal ring delivery of hormone replacement therapy – a review. Expert Opin Pharmacother. 2003;4(2):201–212.
   PubMed Web of Science ®Google Scholar
• Hamada AL, Maruo T, Samoto T, et al. Estradiol/progesterone-releasing vaginal rings for hormone replacement therapy in postmenopausal women. Gynecolog Endocrinol. 2003;17(3):247–254.
   PubMed Web of Science ®Google Scholar
• Maruo T, Mishell DR, Jr., Ben-Chetrit A, et al. Vaginal rings delivering progesterone and estradiol may be a new method of hormone replacement therapy. Fertil Steril. 2002;78(5):1010–1016.
   PubMed Web of Science ®Google Scholar
• Nash HA, Alvarez-Sanchez F, Mishell DR, Jr., et al. Estradiol-delivering vaginal rings for hormone replacement therapy. Am J Obstet Gynecol. 1999;181(6):1400–1406.
   PubMed Web of Science ®Google Scholar
• Nachtigall LE. Clinical trial of the estradiol vaginal ring in the U.S. Maturitas. 1995;22:s43–s47.
   PubMed Web of Science ®Google Scholar
• Maruca J, Demers LM, Stumf PG, et al. Development of a vaginal ring for acheiving physiologic levels of 17β-Estradiol in hypoestrogenic women. J Clin Endocrinol Metab. 1982;54(1):208–210.
   PubMed Web of Science ®Google Scholar
• Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol. 2003;102:823–834.
   PubMed Web of Science ®Google Scholar
• Stumpf PG. Selecting constant serum estradiol levels achieved by vaginal rings. Obstet Gynecol. 1986;67(1):91–94.
   PubMed Web of Science ®Google Scholar
• Vartiainen J, Wahlström T, Nilsson CG. Effects and acceptability of a new 17beta-oestradiol-releasing vaginal ring in the treatment of postmenopausal complaints. Maturitas. 1993;17(2):129–137.
   PubMed Web of Science ®Google Scholar
• Farish E, Barnes JF, Rankin M, et al. Effects on climacteric symptoms, bone and lipoprotein metabolism of hormone replacement therapy delivered by estradiol-releasing intravaginal rings: a pilot study. Climacteric. 2003;6(3):211–220.
   PubMed Web of Science ®Google Scholar
• Constantine GD, Simon JA, Pickar JH, et al. Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data. Curr Med Res Opin. 2018;34(12):2131–2136.
   PubMed Web of Science ®Google Scholar
• Algorta J, Diaz M, de Benito R, et al. Pharmacokinetic bioequivalence, safety and acceptability of Ornibel®, a new polymer composition contraceptive vaginal ring (etonogestrel/ethinylestradiol 11.00/3.474 mg) compared with Nuvaring® (etonogestrel/ethinylestradiol 11.7/2.7 mg). Europ J Contracept Reprod Health Care. 2017;22(6):429–438.
   PubMed Web of Science ®Google Scholar
• Brucker C, Karck U, Merkle E. Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing®: results of clinical experience in Germany. Euro J Contracept Reprod Health Care. 2008;13(1):31–38.
   PubMed Web of Science ®Google Scholar
• Szarewski A. High acceptability and satisfaction with NuvaRing use. Eur J Contracept Reprod Health Care. 2002;7(sup2):31–36.
   PubMedGoogle Scholar
• Novák A, de la Loge C, Abetz L, et al. The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception. 2003;67(3):187–194.
   PubMed Web of Science ®Google Scholar
• van Laarhoven JAH, Kruft MAB, Vromans H. In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring. Int J Pharm. 2002;232(1–2):163–173.
   PubMed Web of Science ®Google Scholar